Developing rationally designed, targeted, and individualized therapeutic strategies that will minimize the use of conventional toxic and noxious chemotherapeutics in patients with hematologic malignancies
Hematologic malignancies, including lymphoma, leukemia, and multiple myeloma, affect at least 150,000 people per year in the United States — and most of these diseases remain incurable. At the time of diagnosis, blood cancers are almost always widely spread throughout the body and require systemic and often extremely toxic chemotherapy regimens or risky bone marrow transplantation as treatment. Therefore, while the outcome is uncertain at best, patients require high intensity medical care.
NewYork-Presbyterian/Weill Cornell Medical Center has become a leader in treating hematologic malignancies and developing protocols for testing novel targeted therapies that are more effective and less toxic than traditional approaches.
Thanks to improved genome sequencing and computer technology, the science of treating hematologic malignancies is reaching a transformative stage. For the first time, laboratory and translational science can begin to accurately guide the diagnosis and treatment of individual patients with lymphoid and myeloid neoplasms. Rational deployment of experimental drug regimens has a higher chance than ever to eradicate or at least control currently incurable hematologic malignancies. Key advances have come from extensive genomic resequencing efforts at many institutions, including Weill Cornell and NewYork-Presbyterian.
We believe that curing many more of the most common hematological malignancies is now within reach and that scientific advances leading to such cures can be achieved at the Meyer Cancer Center and its collaborating institutions.
- Myeloid Disorders
- Lymphoid Disorders
- Tumor Immunity & Cell Therapy